The House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug costs and strengthen the Affordable Care Act’s health insurance marketplaces. The legislation’s drug-related provisions would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, and help decrease the time it takes for generic competitors to get to market. The ACA marketplace provisions would provide funding to expand navigator support and outreach to help consumers enroll in individual market coverage, and void a final rule that expanded short-term limited duration health plans. 
 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Senate today failed to pass legislation to address health care affordability. The chamber first voted on a Republican-backed bill that failed by a 51-…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…